Creating an orthogonal gate to the brain

This project aims to revolutionize brain drug delivery by creating a novel orthogonal receptor for efficient transport across the blood-brain barrier, targeting treatments for brain metastatic breast cancer.

Subsidie
€ 1.499.136
2023

Projectdetails

Introduction

Many impairing illnesses ranging from metastatic cancers to neurodegenerative diseases affect the brain. Unfortunately, delivery of therapeutics to the brain is highly challenging due to the blood-brain barrier (BBB). Despite decades of research, no safe and efficient strategy to overcome this barrier has reached clinical application.

Proposed Concept

Here we propose a concept that will revolutionize brain transport: creating a new orthogonal receptor to mediate transport across the BBB. Numerous molecules have been developed to achieve brain delivery via receptor-mediated transport. However, delivery is very limited presumably because no receptor combines three key features:

  1. High transport efficiency
  2. High expression on the BBB
  3. Low expression on peripheral tissues

This results in peripheral tissues acting as a sink and dramatically lowering the therapeutic index of drugs aimed for the brain.

Current Limitations

The greatest limitation of current efforts is trying to solve both selectivity and efficient transport in a single delivery vehicle. Our unprecedented approach is based on dissecting this problem into two parts:

  • Increasing transport efficiency with the new orthogonal receptor OBGate
  • Addressing selectivity with a highly efficient targeted vehicle to express the receptor only at the BBB.

Engineering the Receptor

Since this receptor will not bind any endogenous ligand, its properties and intercellular trafficking can be engineered with minimal alteration of brain homeostasis. This will enable us to unravel the key determinants of BBB transport and to build an ideal transport system.

Selective Expression

Selective expression of this receptor in the brain endothelium will be achieved by engineering a gene delivery nanocarrier mimicking the two-stage viral entry into BBB cells.

Application Example

As an example to prove the efficiency of our system, we will aim to deliver biotherapeutics for the treatment of brain metastatic breast cancer.

Conclusion

Overall, we will open a new gate to the brain that is poised to be paradigm-breaking in the treatment of neurological diseases.

Financiële details & Tijdlijn

Financiële details

Subsidiebedrag€ 1.499.136
Totale projectbegroting€ 1.499.136

Tijdlijn

Startdatum1-6-2023
Einddatum31-5-2028
Subsidiejaar2023

Partners & Locaties

Projectpartners

  • INSTITUT QUIMIC DE SARRIApenvoerder

Land(en)

Spain

Vergelijkbare projecten binnen European Research Council

ERC STG

MANUNKIND: Determinants and Dynamics of Collaborative Exploitation

This project aims to develop a game theoretic framework to analyze the psychological and strategic dynamics of collaborative exploitation, informing policies to combat modern slavery.

€ 1.497.749
ERC STG

Elucidating the phenotypic convergence of proliferation reduction under growth-induced pressure

The UnderPressure project aims to investigate how mechanical constraints from 3D crowding affect cell proliferation and signaling in various organisms, with potential applications in reducing cancer chemoresistance.

€ 1.498.280
ERC STG

Uncovering the mechanisms of action of an antiviral bacterium

This project aims to uncover the mechanisms behind Wolbachia's antiviral protection in insects and develop tools for studying symbiont gene function.

€ 1.500.000
ERC STG

The Ethics of Loneliness and Sociability

This project aims to develop a normative theory of loneliness by analyzing ethical responsibilities of individuals and societies to prevent and alleviate loneliness, establishing a new philosophical sub-field.

€ 1.025.860

Vergelijkbare projecten uit andere regelingen

ERC COG

In Vivo CRISPR-Based Nanoplatform for Gene Editing: A New Disruptive Avenue for Non-Invasive Treatment of Genetic Brain Diseases

This project aims to develop a novel nanoplatform for the safe and efficient delivery of CRISPR gene editing technology to treat genetic brain diseases non-invasively.

€ 2.249.895
ERC POC

Versatile Polypeptide-based Intranasal Drug Delivery Platform(s) to Tackle CNS Disorders.

POLYBRAINT aims to develop an innovative intranasal drug delivery platform to effectively transport biological agents across the blood-brain barrier for treating CNS disorders.

€ 150.000
ERC COG

4D Brain-Targeting Nanomedicines for Treating Neurodegeneration

This project aims to develop advanced 4D-brain-targeting nanoparticles using nanotechnology to effectively deliver treatments for neurodegenerative diseases across the blood-brain barrier.

€ 2.000.000
ERC COG

Drug DELIvery to the brain via CHOroid Plexus targeting

This project aims to explore the blood-CSF barrier as a novel route for delivering therapeutics to the brain, potentially enhancing treatment strategies for CNS disorders.

€ 1.999.756